Btk, a member of the Tec family of kinases, is well-known for its function in B-cell activation and B-cell antigen receptor (BCR) signaling.
Btk is a new target for diseases with abnormal B cell activity because it is essential for B cell development and activation through the BCR signaling pathway. The human primary immune deficiency disease X-linked agammaglobulinemia (XLA), which is caused by a mutation in the Btk gene, highlights the importance of Btk, a kinase that is only expressed in B cells and myeloid cells.The BCR signaling pathway depends on Btk in many ways. B cell receptor oligomerization, Syk and Lyn kinase activation, and Btk kinase activation are all caused by antigen binding to the BCR. When Btk is activated, it joins forces with proteins like BLNK, Lyn, and Syk to form a signaling complex that phosphorylates phospholipase C (PLC)2. This results in transcriptional changes that promote B cell survival, proliferation, and/or differentiation by releasing intracellular Ca2+ stores downstream and propagating the BCR signaling pathway through extracellular signal-regulated kinase and NF-B signaling.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V121811 | (E/Z)-Rilzabrutinib | 1575591-66-0 | (E/Z)-Rilzabrutinib is the cis-trans isomer of Rilzabrutinib. |
|
V87996 | (R)-Acalabrutinib | 1952316-43-6 | (R)-Acalabrutinib ((R)-ACP-196) is an isomer of Acalabrutinib. |
|
V87995 | (R)-NX-2127 | 3024312-52-2 | (R)-NX-2127 (compound 28) is an orally active Bruton's tyrosine kinase (Btk) degrader. |
|
V115563 | (R,R)-Bexobrutideg | 2649400-33-7 | (R,R)-Bexobrutideg is the (R,R)-enantiomer of bexobrutideg. |
|
V109231 | (R,R)-Birelentinib | 2662512-14-1 | (R,R)-Birelentinib ((R,R)-DZD8586) (compound 14) is a potent BTK inhibitor with IC50 values of 0.7 nM for wild-type BTK and 0.86 nM for BTK C481S mutant. |
|
V119798 | (Rac)-Ibrutinib alkyne | 936563-91-6 | (Rac)-ibrutinib alkyne (compound 8) is a Btk inhibitor with an IC50 of 0.72 nM. |
|
V0647 | (Z)-LFM-A13 | 244240-24-2 | (Z)-LFM-A13 (LFM-A1-3) is a novel, potent and specific Brutons tyrosine kinase (BTK) inhibitor with potential anticancer activity. |
|
V123855 | 2-(Bromomethyl)acrylic acid | 72707-66-5 | 2-(Bromomethyl)acrylic acid is a Bruton's tyrosine kinase (BTK) inhibitor. |
|
V89055 | ABBV-992 | 2792171-84-5 | ABBV-992 is a potent and selective BTK inhibitor. |
|
V108927 | Acalabrutinib maleate | 2242394-65-4 | Acalatinib maleate is an orally effective, irreversible, and highly selective second-generation BTK inhibitor. |
|
V128793 | AMX5160 | 2639293-95-9 | AMX5160 is an orally effective BTK inhibitor with an IC50 of 0.98 nM against mutant BTKC481S. |
|
V87994 | BIIB129 | 2770960-52-4 | BIIB129 is a covalent, selective, blood-brain barrier-penetrating small molecule inhibitor of Bruton's tyrosine kinase (BTK). |
|
V118843 | BTK C481R Recombinant Human Active Protein Kinase | Bruton's tyrosine kinase (BTK) plays a key role in the B cell antigen receptor (BCR) signaling pathway. | |
|
V130711 | BTK degrader-1 intermediate | 2377643-84-8 | BTK degrader-1 intermediate is an intermediate in the synthesis of BTK degrader-1. |
|
V114529 | BTK degrader-2 | 2649400-05-3 | BTK degrading enzyme-2 (Example 2) is a bifunctional BTK degrading enzyme that degrades BTK via the ubiquitin-proteasome pathway. |
|
V5248 | BTK inhibitor 27 | 2230724-66-8 | BTK inhibitor 27, compound 27 in the cited reference below, is apyrrolo[2,3-d]pyrimidine based BTK inhibitor with an IC50 of 0.11 nM for Btk and inhibits B cell activation in hWB with an IC50 of 2 nM. |
|
V119634 | BTK ligand 16 | BTK ligand 16 is a BTK ligand that can be used to synthesize TQ-3959. | |
|
V130714 | BTK ligand-17 | BTK ligand-17 is a BTK ligand. | |
|
V130715 | BTK ligand-19 | BTK ligand-19 is a PROTAC ligand for BTK, used to synthesize PROTAC-based BTK degrader PROTAC BTK degrader-14. | |
|
V130716 | BTK ligand-20 | BTK ligand-20 is a BTK ligand. |